Even so, anti-Her2 treatments in MIBC have not been as encouraging17, 18, 19, 20 and despite best practice patient selection by fluorescence in-situ hybridization (FISH) and immunohistochemistry (IHC), question whether bladder cancer can respond to Her2 targeted therapy. This evidence concerns the gene ERBB2 and urinary bladder carcinoma.